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Abstract
Introduction: The present study is a pilot prospective safety evaluation of a new closed loop computerised
protocol on ventilation and oxygenation in stable, spontaneously breathing children weighing more than 7 kg,
during the weaning phase of mechanical ventilation.
Methods: Mechanically ventilated children ready to start the weaning process were ventilated for five periods of
60 minutes in the following order: pressure support ventilation, adaptive support ventilation (ASV), ASV plus a
ventilation controller (ASV-CO2), ASV-CO2 plus an oxygenation controller (ASV-CO2-O2) and pressure support
ventilation again. Based on breath-by-breath analysis, the percentage of time with normal ventilation as defined by
a respiratory rate between 10 and 40 breaths/minute, tidal volume > 5 ml/kg predicted body weight and end-tidal
CO2 between 25 and 55 mmHg was determined. The number of manipulations and changes on the ventilator
were also recorded.
Results: Fifteen children, median aged 45 months, were investigated. No adverse event and no premature
protocol termination were reported. ASV-CO2 and ASV-CO2-O2 kept the patients within normal ventilation for,
respectively, 94% (91 to 96%) and 94% (87 to 96%) of the time. The tidal volume, respiratory rate, peak inspiratory
airway pressure and minute ventilation were equivalent for all modalities, although there were more automatic
setting changes in ASV-CO2 and ASV-CO2-O2. Positive end-expiratory pressure modifications by ASV-CO2-O2 require
further investigation.
Conclusion: Over the short study period and in this specific population, ASV-CO2 and ASV-CO2-O2 were safe and
kept the patient under normal ventilation most of the time. Further research is needed, especially for positive end-
expiratory pressure modifications by ASV-CO2-O2.
Trial registration: ClinicalTrials.gov: NCT01095406
Introduction
The worldwide increase in patient complexity, more
concern for quality and safety, and a shortage of
resources are the challenging terms of the equation
many physicians and respiratory therapists have to face
nowadays [1-3]. Mechanical ventilation is one of the
life-saving techniques used at the bedside that is also
associated with complications, including ventilator-
induced lung injury and ventilator-associated pneumonia
[4,5]. To decrease the duration of mechanical ventila-
tion, there is evidence suggesting that the use of a writ-
ten protocol is helpful [6]. Writing and reading
protocols are time consuming, resulting in fluctuation in
protocol implementation and compliance; instructions
cannot be explicit enough, resulting in variable interpre-
tation of the protocol; and they are specific to one orga-
nisation, making transfer to another institution difficult.
To overcome these limiting factors, protocols have been
computerised and there is convincing evidence showing
that computerised protocols may help to manage and
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wean adult patients [7,8] and children with severe lung
diseases [9,10].
A new computerised protocol with closed loop control
of ventilation and oxygenation (IntelliVent®; Hamilton
Medical AG, Bonaduz, Switzerland) has recently become
available and has been investigated in adult patients
[11]. The present study is a pilot prospective evaluation
of this new closed loop computerised protocol in stable
mechanically ventilated children during the weaning
phase.
Materials and methods
The study - which was approved by the Sainte Justine
Hospital ethical committee (Montreal, Canada) and by
Health Canada and was registered on clinicaltrials.gov
(NCT01095406) - was realised between January 2010
and January 2011 in the paediatric ICU of the Sainte
Justine Hospital, Montreal, Canada. Signed informed
consent was obtained from legal representatives as well
as consent for publication of this manuscript and
accompanying images.
Patients
During the study period, all consecutive admitted criti-
cally ill children under mechanical ventilation for at
least 12 hours, younger than 18 years old, having pre-
dicted body weight (PBW) ≥ 3 kg and body mass index
< 40 kg/m2 were screened daily for the study 5 days a
week (Monday to Friday). PBW was the weight at the
50th percentile for age and sex from the National Cen-
ter of Health Statistics growth chart.
The study was in essence a pilot investigation and was
designed primarily to evaluate the safety of the new
computerised protocol. Children were therefore included
if they fulfilled the following criteria: able to breathe
spontaneously; ventilated with proximal airway plateau
pressure ≤ 25 cmH2O, positive end-expiratory pressure
(PEEP) ≤ 8 cmH2O, with fraction of inspired oxygen
(FiO2) ≤ 60% to keep oxygen saturation from pulse oxy-
metry (SpO2) ≥ 95%, and arterial partial pressure of
CO2 < 70 mmHg on the last arterial blood gas; endotra-
cheal tube leakage < 20% of the inspired tidal volume
(VT), because the new computerised protocol requires
correct information on VT; arterial partial pressure of
CO2 versus partial pressure in end-tidal CO2 (PEtCO2)
difference ≤ 7 mmHg; or not receiving muscle relaxant,
vasopressor or inotropic medication (except dopamine <
5 μg/kg/minute).
Children with a previous history of mechanical venti-
lation (more than 1 month) or tracheotomy, severe neu-
romuscular disease, cyanotic congenital heart disease
and primary pulmonary hypertension were excluded, as
well as brain-death children and children receiving pal-
liative care.
An analysis was planned after the inclusion of five
patients (run-in phase) because there was no clinical
experience of this mode of ventilation. The analysis of
the run-in phase showed that children with PBW < 7 kg
had an increase in minute ventilation (MV) because of
technical reasons (high apparatus dead space with the
S1 device due to the proximal flow sensor + mainstream
CO2 analyser in series). The investigators decided to
only include children with PBW > 7 kg. The four
patients under 7 kg PBW and already included in the
run-in phase were not analysed, although they went
through the study without adverse effects (see Safety
evaluation below).
Study design
All included patients were prospectively enrolled in a
sequential nonrandomised study during which they
received five consecutive 60-minute periods of ventila-
tion (Figure 1): pressure support ventilation (PSV) using
the ventilator already connected to the patient (Servo-i;
Maquet Gmbh & Co. KG, Rastatt, Germany) with the
level of inspiratory pressure (Pinsp) set by the attending
intensivist prior to the inclusion (PSV_before); adaptive
support ventilation (ASV) using a functional S1 proto-
type ventilator (Hamilton Medical AG); ASV with the
CO2 controller activated (ASV-CO2); ASV with the CO2
and the O2 controller activated (ASV-CO2-O2); and PSV
using the Servo-i ventilator at the initial level of support
(PSV_after).
Throughout the ventilation period with the S1 device
and for safety reasons, a trained physician remained at
the bedside.
The PSV mode was given with the servo-i ventilator
because the S1 device had only the new computerised
protocol and ASV inside. The ventilation modes were
not randomised as we had to ventilate the children in
PSV before and at the end of the study, and randomis-
ing the modes would require changing the ventilator in
a randomised order as well, which was not allowed for
safety reasons.
Ventilatory modalities
ASV is a ventilatory modality commonly used in adults
[11,12] where, for a given MV set by the user according
to the clinical conditions and arterial blood gases, the
ventilator automatically selects an optimal combination
of respiratory rate (RR) and VT based on the breath-by-
breath estimation of the expiratory time constant. The
level of support (mandatory rate and Pinsp) is automati-
cally adjusted on a breath-by-breath basis to keep the
patient as close as possible to the optimal RR and VT. If
the patient breathes spontaneously, this mode works as
a volume target-pressure regulated mode with a user-set
MV guarantee. If not, the ASV mode works as a
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pressure control mode with a prescribed MV. In ASV,
the MV is the parameter that is controlled and set by
the user. To further control the VT (and more specifi-
cally to reduce the VT) or to limit Pinsp, the user must
decrease the MV and the maximum Pinsp allowed (pres-
sure limitation). At the bench, in doing so it has been
recently shown that ASV was able to generate lower VT
and Pinsp compared with the ARDSnetwork recommen-
dations [13]. However, in some clinical studies when the
maximum allowed pressure is permissive (60 cmH2O),
high VT has been reported with ASV [14]. In our study,
MV in ASV was set to match the MV measured during
PSV_before. PEEP and FiO2 were set as during PSV_be-
fore. The pressure limitation was set to limit the Pinsp to
25 cmH2O.
ASV-CO2 is an evolution of ASV where MV is not set
by the user but is automatically adjusted to keep the
patient within ranges of RR and PEtCO2, captured at
the proximal airway using the S1 flow sensor (PN
279331, single-use flow sensor linear between -120 and
120 l/minute with ± 5% error of measure; Hamilton
Medical AG) and a mainstream CO2 analyser (Capno-
stat 5, mainstream sensor with accuracy ± 5% for
PEtCO2 between 41 and 70 mmHg, dead space 5 ml;
Hamilton Medical AG). The target range of RR is
defined by a lower limit based on the Otis concept of
optimal RR to minimise the work of breathing [15], and
an upper limit depending on the actual MV; the higher
the MV, the higher the upper RR limit. Pinsp increases
when the patient RR is above the upper RR limit; Pinsp
decreases when the patient RR is below the lower RR
limit. Filtered PEtCO2 is present in the background to
keep the patient below the upper PEtCO2 acceptable
value (Figure 2). Ventilation changes are made on a
breath-by-breath basis.
ASV-CO2-O2 includes the above-described ASV-CO2
regulation plus an automatic adjustment of PEEP and
FiO2 based on SpO2 monitoring included in the ventila-
tor. SpO2 is obtained from a finger probe using standard
technology, plus proprietary filtering and quality assess-
ment before entering the algorithm: when SpO2 is
below a user-adjustable value, FiO2 or PEEP is increased
(Figure 2). These ventilation changes are made on a
breath-by-breath basis. The choice between FiO2 and
PEEP increase is based on the ARDSnetwork tables [16]
with user inputs regarding maximal and minimal PEEP
values. The FiO2 controllers and the PEEP controller
can be activated or deactivated independently. In the
present study both controllers were activated, but
according to local policies regarding PEEP settings the
minimal PEEP and maximal PEEP were respectively set
at 5 and 10 cmH2O.
The investigators remained at the bedside during the
entire duration of the study and were allowed to switch
back to manual adjustment of the settings. As for any
mode of ventilation, the user has to set alarms for VT,
for airway pressure as well as for monitoring parameters
such as SpO2 and PEtCO2.
Data collection
Patient characteristics including demographic data, diag-
nosis, severity scores, clinical data at inclusion and out-
comes were collected from the charts. When connected
to the S1 device, monitoring values (including SpO2,
PEtCO2 and mechanical ventilation monitoring), settings
and alarms were recorded on a breath-by-breath basis
using a dedicated data-logging system attached to the
ventilator. Minute-to-minute data from the Servo-i were
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Figure 1 Study protocol. Included patients were prospectively enrolled in a sequential study during which they received five consecutive 1-
hour periods of ventilation. PSV, pressure support mode; ASV, adaptive support ventilation mode; ASV-CO2, ASV and CO2 controller; ASV-CO2-O2,
ASV-CO2 and oxygen controller.
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Figure 2 Functional algorithm of the ventilation and oxygen controller. (A) Ventilation controller. The partial pressure in end-tidal CO2
(PEtCO2) values are given with the quality index and derived from the mainstream CO2 sensor with proprietary algorithms as a surrogate of
arterial partial pressure of CO2. PEtCO2min and PEtCO2max are adjustable by the user and depend on the patient’s severity estimated by the
level of inspiratory pressure; that is, the higher the inspiratory pressure and the more permissive the PEtCO2 limits. As an example and by default
for an inspiratory pressure of 10 cmH2O, PEtCO2min is 35 mmHg and PEtCO2max is 41 mmHg. (B) Oxygen controller. The oxygen saturation
from pulse oxymetry (SpO2) limits (SpO2safety and SpO2min) are adjustable by the user and depending on the patient’s severity estimated by
the positive end-expiratory pressure (PEEP) level; that is, the higher the PEEP level and the more permissive the SpO2 limits. As an example and
by default for a PEEP level of 5 cmH2O, SpO2safety is 88%, SpO2min is 93% and SPO2max is 98%. The PEEPopt is defined according to a PEEP-
fraction of inspired oxygen (FiO2) table and PEEPmax set by the user. The patient SpO2 is provided with a quality index and is derived from the
pulse oxymeter with proprietary algorithms for artefact and motion rejections. MV, minute ventilation; RR, respiratory rate.
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Breath-by-breath data were analysed ex vivo to calcu-
late the number of normal breaths as defined by 10
breaths/minute < RR < 40 breaths/minute, VT > 5 ml/
kg PBW and 25 mmHg < PEtCO2 < 55 mmHg. The pri-
mary end point of the study was the percentage of time
spent with normal ventilation, defined as the number of
normal breaths out of the total number of breaths col-
lected. During PSV_before and PSV_after, PEtCO2 was
dropped from the definition as it was not recorded with
the Servo-i ventilator.
The number of ventilation setting changes was com-
pared between the five consecutive 60-minute periods of
ventilation. A ventilation setting change corresponded to
a modification of PEEP or FiO2 in any ventilation mode,
a change of Pinsp in PSV or a change of minute volume
in ASV, ASV-CO2 or ASV-CO2-O2.
Safety evaluation
Safety was evaluated by recording adverse events as
defined by ISO 14155 standards (ISO 14971:2007, Medi-
cal devices – Application of risk management to medical
devices) and by the number of switch back to PSV or to
controlled ventilation by the intensivist present at the
bedside, whatever the reason. The protocol was termi-
nated and the child ventilated with the previous conven-
tional ventilation if a sustained change was
demonstrated in any of the following: decrease in SpO2
< 92% requiring increase in FIO2 > 60%; increase in
PEtCO2 above the value before connection with the S1
device, requiring an increase of positive Pinsp > 25
cmH2O above PEEP; increase in heart rate > 180 beats/
minute for 15 minutes; increase in RR > 60 breaths/
minute for 15 minutes; or uncontrolled agitation.
Sample size
There were no previously existing data on the percentage
of time spent with normal ventilation in children during
mechanical ventilation. A similar study in adults observed
that patients in PSV mode spent 66 ± 23% in the normal
ventilation range compared with 93 ± 8% of patients ven-
tilated with a closed loop computerised protocol [17].
From this study [17], we calculated that 16 patients
would be required to find a statistical difference for such
a difference with an a risk of 0.05 and a b risk of 0.9.
Statistical analysis
As the parameters studied did not have a normal distri-
bution, data are shown as the median with 25% and
75% interquartile ranges. Medians were compared using
a Kruskal-Wallis one-way analysis of variance on ranks
and paired tests when P < 0.05 using Sigma Stats for
Windows version 3.5 (Systat Software, Inc., Richmond,
CA, US).
Results
During the study period, 196 patients were screened and
15 patients with PBW > 7 kg were included. These 15
patients were ventilated for a median of 55 hours before
inclusion (Table 1). One patient (Patient 12, Table 1)
did not undergo the ventilation periods with the S1
device due to the use of a neonatal flow sensor by mis-
take, which did not allow ventilating in the ASV mode,
and was therefore excluded from analysis. The remain-
ing 14 patients went through the study without side
effects, without switching to PSV or controlled ventila-
tion, or without early protocol termination when they
were ventilated with the S1 ventilator.
Compared with PSV_before (93% (79 to 95%)) and
PSV_after (96% (83 to 100%)), ASV, ASV-CO2 and
ASV-CO2-O2 kept the patients within normal ventila-
tion for a similar percentage of time (respectively: 93%
(80 to 95%), 94% (91 to 96%) and 94% (87 to 96%))
(Table 2).
The VT, RR, peak inspiratory airway pressure (Paw-
peak) and MV were equivalent with all modalities.
PEtCO2 and SpO2 were also equivalent between ASV,
ASV-CO2 and ASV-CO2-O2 (Table 2). The standard
deviation to estimate the variability of Paw-peak was
much higher with ASV, ASV-CO2 and ASV-CO2-O2 as
compared with PSV (Figure 3). As compared with ASV,
there were significantly more ventilator setting adjust-
ments (automatic) in ASV-CO2 and ASV-CO2-O2 (77
(57 to 120) per patient and 80 (32 to 272) per patient,
respectively) (Table 2).
In four patients, during the 60-minute period with
ASV-CO2-O2, an automatic increase of PEEP from 5
cmH2O to 7 to 9 cmH2O was observed due to a transi-
ent decrease in SpO2. The physician manually returned
the PEEP to 5 cmH2O because it was not in his practice
to increase PEEP in this situation.
The median total duration on the ventilator was 97
hours (55 to 207 hours) and the length of stay in the
ICU was 5 days (4 to 13 days). At 28 days after the
inclusion, all patients were alive, none was on mechani-
cal ventilation and five patients remained in the hospital.
Discussion
ASV alone or combined with the automatic adjustment
of minute volume was safe and provided a similar
breath pattern as compared with PSV. This was
achieved, however, with more ventilator automatic
adjustments and more variability in Paw-peak as com-
pared with ASV and PSV. The apparatus dead space
with the S1 device due to the proximal flow sensor +
mainstream CO2 analyser in series restrained the venti-
lation to children with body weight > 7 kg. As the
patients were in a stable situation and not hypoxemic,
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little information was obtained regarding the oxygena-
tion controller. In four patients, however, an automatic
increase in PEEP was observed that was not considered
usual practice by the physician in charge.
The present pilot study has several limitations that
need to be addressed before raising some conclusions.
First, comparing ASV, ASV-CO2 and ASV-CO2-O2 from
the S1 device with PSV given with another ventilator is
arguable. Even if the aim of the study was not to com-
pare the performance of each mode in supporting the
patient, this may indeed impact on the primary endpoint
- that is, the time spent with normal ventilation, which
was defined based on the RR, VT and PEtCO2. Further-
more, the data were acquired differently with the S1
device (breath by breath) as compared with the Maquet
ventilator (minute by minute, equivalent to a filtering).
PEtCO2 was also not part of the definition of normal
breathing in PSV, and PEtCO2 is known to show high
fluctuation on both sides in spontaneously breathing
patients [18]. Whether minute-by-minute filtering and
not having PEtCO2 in PSV are overestimating the time
in normal ventilation during PSV is questionable. As the


















1 36 12 0 12 Rhabdomyosarcoma 21 15 100 0.25 5 36
2 195 57 0 2 Scoliosis-
encephalopathy
26 13 98 0.25 5 34
3 93 27 3 2 Polytraumatism 240 15 98 0.30 5 40
4 28 14 2 3 Liver transplantation 72 25 98 0.40 7 46
5 59 17 0 1 Cranio-facial surgery 56 17 98 0.25 5 47
6 22 14 3 1 Laryngitis 44 15 96 0.35 5 38
7 187 38 0 2 Congenital scoliosis 55 21 99 0.25 5 39
8 29 10 3 2 Septic shock 203 26 95 0.40 5 48
9 32 14 1 3 Encephalitis 46 15 100 0.30 5 38
10 54 16 0 1 Thyreoglosse cyst 31 15 99 0.45 5 39
11 9 7 3 1 Severe laryngitis 41 18 98 0.35 5 41
12 62 18 1 11 Pharyngeal abscess 38 17 98 0.21 5 37
13 45 15 13 1 Aspiration-
encephalopathy
235 11 98 0.30 5 59
14 16 10 3 14 Encephalitis 66 15 100 0.25 5 29
15 165 49 2 12 Encephalopathy 75 15 98 0.30 5 40
Median 45 15 2 2 55 15 98 0.30 5 39
IQR25 29 13 0 1 40 15 98 0.25 5 38
IQR75 78 23 3 7 73 18 99 0.35 5 43
PBW, body weight; PIM2, Paediatric Index of Mortality (percentage of risk of death) [29]; PELOD, Paediatric Logistic Organ Dysfunction score [30]; MV, mechanical
ventilation; Ppeak, peak pressure at the proximal airway; SpO2, pulse oxygen saturation; FiO2, inspired oxygen fraction; PEEP, positive end-expiratory pressure;
PaCO2, arterial partial pressure of CO2; IQR25 and IQR75, 25% and 75% interquartile range.
Table 2 Time spent with normal ventilation, ventilation pattern, peak airway pressure, PEtCO2 and SpO2
PSV_before ASV ASV-CO2 ASV-CO2-O2 PSV_after P value
Normal ventilation (% of the recording time) 93 (82 to 95) 94 (82 to 96) 95 (92 to 96) 95 (89 to 96) 97 (85 to 100) NS
Number of ventilation setting changes/patient 0 (0 to 0) 0 (0 to 0) 78 (58 to 119) 81 (35 to 250) 0 (0 to 0) < 0.001*
Respiratory rate (breaths/minute) 17 (14 to 21) 21 (18 to 24) 23 (19 to 25) 22 (18 to 27) 20 (16 to 26) NS
Tidal volume (ml/kg) 8.3 (7.1 to 9.3) 8.7 (7.7 to 9.7) 8.9 (8.2 to 9.7) 8.4 (7.8 to 9.7) 7.9 (6.7 to 8.9) NS
Paw-peak (cmH2O) 16 (15 to 18) 15 (14 to 22) 16 (14 to 19) 17 (15 to 21) 15 (14 to 19) NS
PEtCO2 (mmHg) - 43 (39 to 45) 43 (40 to 45) 43 (39 to 47) - NS
SpO2 (%) - 98 (95 to 100) 99 (96 to 100) 98 (95 to 100) - NS
Results of time spent with normal ventilation, ventilation pattern, peak airway pressure, partial pressure of end-tidal CO2 (PEtCO2) and pulse oxygen saturation
(SpO2) during the five 1-hour periods investigated. Results given as the median with 25% to 75% interquartile range. Normal ventilation is the percentage of
time with normal breath as defined by 10 breaths/minute < respiratory rate < 40 breaths/minute, tidal volume > 5 ml/kg predicted body weight and 25 mmHg
< PEtCO2 < 55 mmHg. PSV, pressure support ventilation; ASV, adaptive support ventilation, ASV-CO2, ASV plus the CO2 controller; ASV-CO2-O2, ASV-CO2 plus the
oxygen controller; Paw-peak, peak proximal airway pressure; NS, P > 0.05. *P < 0.001 for ASV versus ASV-CO2 and for ASV versus ASV-CO2-O2.
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S1 ventilator did not have the PSV mode, however, the
study had to be carried out with the methodology
described above.
Second, the different modes of ventilation were given
sequentially and without randomisation. The total dura-
tion of the study was 5 hours and very obviously the
patient’s conditions may change over such a long period.
However, the patient ’s respiratory conditions in
PSV_after as compared with PSV_before were not differ-
ent (Table 2).
Third, the study was finally underpowered (14 patients
analysed as compared with the 16 patients required by
the power calculation). This was because of four
patients weighing < 7 kg and not being analysed. In one
patient the new computerised protocol was also unable
to work because of the wrong flow sensor (neonatal
flow sensor) being on the device. However, an increased
number of patients would probably not achieve statisti-
cal significance as the observed time spent in normal
ventilation during PSV mode was higher than expected
(93% instead of 66% as expected from a previous adult
study [17]).
Fourth, the different modes were investigated over a
short period of time (60 minutes) and in a very specific
subpopulation of stable patients during the weaning
phase. It is indeed impossible to estimate the safety of
such a closed loop computerised protocol in more criti-
cally ill patients. The clinical impact of such a mode of
ventilation is also not addressed by the present study.
These studies will be the next steps.
Finally, the PEEP controller - which is probably the
most critical in terms of safety - was set to very conser-
vative working conditions (minimal PEEP 5 cmH2O and
maximal PEEP 10 cmH2O). In four patients an increase
of PEEP from 5 cmH2O to 7 to 9 cmH2O was observed
due to a transient decrease in SpO2. The physician
manually returned the PEEP to 5 cmH2O because it was
not in his practice to increase PEEP in this situation.
The present study is therefore not able to raise any con-
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Figure 3 Peak airway pressure of children during the 1-hour periods of mechanical ventilation. Peak inspiratory airway pressure (Paw-
peak; median and standard deviation (SD)) of the 14 children included during the five 1-hour periods of mechanical ventilation. The median
values were not statistically different, but the SDs of individual breath-by-breath values (right panel) were significantly higher, suggesting more
variability in adaptive support ventilation (ASV), ASV and CO2 controller (ASV-CO2) and ASV-CO2 and oxygen controller (ASV-CO2-O2) as compared
with pressure support ventilation (PSV).
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protocol, and further data are needed on the optimal
PEEP during the weaning phase.
The present pilot study is therefore exploratory and
can only indicate that in this stable population, over a
short period of time (60 minutes) and within the experi-
mental conditions (PEEP limited and manually con-
trolled), ASV-CO2 and ASV-CO2-O2 were safe.
Additional studies are definitely required before raising
any conclusion on safety or effectiveness during longer
period of ventilation and in patients with more critical
conditions.
Interesting observations can be raised, however, from
the present study. First, in babies with body weight < 7
kg, the apparatus dead space (proximal flow sensor in
series with the PEtCO2 sensor) was relatively high, indu-
cing an increase in MV as compared with PSV. As
already shown in adult patients, the dead-space-related
increase in MV and subsequent changes in the patient’s
optimal RR and VT combination is hardly predictable
[19]. As most of the children admitted to the paediatric
ICU weigh < 7 kg [20], it is critical to reduce the appa-
ratus dead space as much as possible before using such
a computerised protocol.
Second, more ventilator automatic adjustments and
more variability in Paw-peak were observed in ASV-
CO2 and ASV-CO2-O2 as compared with ASV and PSV
with ultimately equivalent PEtCO2. This is most prob-
ably due to the patients’ subclinical changing conditions
that are taken into account by ASV-CO2 and not with
ASV or PSV. More variable ventilation may have an
impact on lung recruitment, as suggested in atelectatic
animal models [21,22], and may have an impact on
patient comfort, as suggested by studies on variable
modes using pressure support [23,24].
Third, although designed for children and adult
patients, and already on the market for 10 years, publi-
cations are lacking on ASV in children. In the very first
publication from Laubscher and coworkers in 1994 [25],
some paediatric patients were included but ASV was
applied only for a couple of minutes to test the start-up
procedure in selecting the VT and RR. To our best
knowledge, ASV has never been compared with PSV in
the paediatric population. Bearing in mind the above-
mentioned limitations and publications from adult
populations reporting higher VT with ASV when the
pressure limitation is high [14], it is worth noting that
breath patterns with both modes were not drastically
different. Once again, this would deserve additional
investigation.
Finally, although not really challenged by the popula-
tion enrolled in the study, an automatic control of FiO2
based on SpO2 has been already investigated in neonates
[26,27] and in adults [28], with increased time spent
with adequate SpO2 when compared with usual care.
The present study is in line with these previously pub-
lished results.
Conclusion
The present pilot prospective study shows the feasibility
of using a closed loop computerised protocol on ventila-
tion and oxygenation over a short time period in stable,
spontaneously breathing paediatric patients starting the
weaning process. Over the study period, children with
body weight > 7 kg were kept with normal ventilation
most of the time and no safety issues were reported.
Future studies should be designed to address safety and
effectiveness of such a closed loop computerised proto-
col as compared with conventional ventilation in chil-
dren with more challenging respiratory conditions and
over a longer period of time.
Key messages
• A closed loop computerised protocol seems feasi-
ble in paediatric ventilated patients during the wean-
ing phase.
• Compared with PSV, the closed loop computerised
protocol may keep patients within normal ventilation
for a similar percentage of time.
• Compared with PSV, the closed loop computerised
protocol seems to generate more airway pressure
variability.
• Compared with PSV, the closed loop computerised
protocol may adjust the ventilator more often.
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volume.
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